Evidence map›Paper›PMID 42380318›Full record

Articlenpj drug discovery2026

Deep learning-driven integrated pipeline for de novo design and synthesis of antimicrobial peptides.

Jiahui Liu, Yun Chen, Jian Tang, Xupu Xing, Jin-Shun Lin, Juping Sun, Xin-Hui Xing, Juan Li, Can Yang Zhang

Abstract read
In one paragraph

Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiahui Liu *Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Yun Chen *Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Jian TangInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Xupu XingInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Jin-Shun LinInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Juping SunInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Xin-Hui XingInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
Juan LiEnergy and Transportation Domain, Beijing Institute of Technology, Zhuhai, China.
Can Yang ZhangInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China. zhang.cy@sz.tsinghua.edu.cn.

Funding

Guangdong Innovative and Entrepreneurial Research Team Program 2023ZT10C040Key Research and Development Program of the Ministry of Science and Technology 2023YFA0913600National Natural Science Foundation of China 22278242Science, Technology and Innovation Commission of Shenzhen Municipality KCXFZ20230731094459001
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics against bacterial infections. However, the discovery of AMPs is impeded by the limitations of biochemical screening and the difficulty computational approaches face in balancing efficacy with structural diversity. We proposed an integrated "generation-evaluation-validation" framework to facilitate de novo discovery of AMPs. First, we constructed a soft prompt-tuned ProtGPT2 to efficiently generate candidates AMPs with both novel structures and promising therapeutic potential. Secondly, we adopted a multiple-choice learning ensemble model that enables high-confidence evaluation of candidates via a dynamic voting network. Finally, antimicrobial experiments were used to validate the activity of top-ranked de novo AMPs by monitoring bacterial surface changes. Out of nine candidates, four exhibited potent strain-specific activity, while two demonstrated broad-spectrum efficacy. All tested AMPs exhibited strong biofilm inhibition, potent membrane disruption, and minimal hemolysis, indicating significant therapeutic potential. With strong generalizability and versatility beyond AMPs, the proposed framework's modular design will facilitate adaptation to diverse peptide design tasks in the future. By integrating soft prompt tuning, multimodal ensemble learning, and experimental verification, this framework presents a practical and scalable strategy for rapid, resource-efficient de novo peptide discovery, particularly suited for applications where experimental throughput and cost are critical constraints.

Identifiers

PMID42380318
PMCPMC13267055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.